



ACIP Recommendations for Human Rabies Prevention Work Group

Sharon Frey, MD, FACP, FIDSA

Saint Louis University School of Medicine

On behalf of the

ACIP Rabies Work Group

Advisory Committee on Immunization Practices

October 25, 2018

Work Group Members

ACIP Members

Sharon Frey (chair)

José R. Romero

Liaison Representatives

AAP- Elizabeth Bennett

AAFP- James Stevermer

NACCHO- Matt Zahn

APhA- Karl Hess

NACI- Julie Emili and Rob Stirling

FDA- Paula Agger and Robin Levis

NASPHV- Katie Brown and Sally Slavinski

APHL-Michael Pentella

Additional Subject Matter Experts

Susan Moore

Deborah Briggs

CDC

*Rabies Work Group leads – Jesse Blanton
and Agam Rao*

*Division of Global Migration and
Quarantine- Kristina Angelo*

Immunization Safety Office – Pedro Moro

Work Group Purpose and Goals

- To provide a forum for discussion to update the 2008 and 2010 ACIP recommendations on human rabies prevention
- Members will review new any existing data and provide individual input on topics that may inform changes in recommendations
- Work group newly formed; first meeting was October 2018

Need for Updated Recommendations

- Rabies is an acute and fatal encephalomyelitis but is preventable
- > 200,000 persons in US exposed to rabies suspect animals / year
- >30,000 persons receive post-exposure prophylaxis (PEP) / year
- Rabies PEP is safe and efficacious but costs are high
- 2008: ACIP recommendations comprehensively updated; 2010: PEP schedule updated
- In interim, new data and World Health Organization (WHO) updated recommendations



**Human Rabies Prevention —
United States, 2008**
Recommendations of the
Advisory Committee on Immunization Practices



**Use of a Reduced (4-Dose) Vaccine
Schedule for Postexposure Prophylaxis
to Prevent Human Rabies**
Recommendations of the Advisory Committee
on Immunization Practices


Terms of Reference DRAFT

- Review the epidemiology and burden of rabies exposures and PEP administration in the United States
- Review evidence-based recommendations regarding use of rabies vaccine(s) and immunoglobulin products among various populations for topics including the pre-exposure prophylaxis schedule, route of vaccine administration, amount and location of rabies immune globulin, and timing of serologic monitoring
- Review efficacy, immunogenicity, safety, cost-effectiveness, route and location of vaccine administration, and vaccination schedules of rabies vaccine(s) for pre- and postexposure prophylaxis

Terms of Reference DRAFT continued

- Review rabies exposure risk for the general population and by occupational and recreational groups (e.g., veterinarians, laboratorians, travelers)
- Evaluate the effectiveness and costs to adhere to current assessment guidelines and ACIP serological monitoring recommendations
- Review evidence generated for new recommendations of the World Health Organization and identify where additional evidence generation may be necessary to inform recommendations
- Identify areas in need of further research for informing future vaccine and immune globulin recommendations

Tentative Timeline (Subject to Change)



Acknowledgements

CDC Technical Work Group and Subject Matter Experts

Brett Petersen

Ryan Wallace

James Ellison

Emily Pieracci

Sathesh Panayampalli

Anna Mandra

Jesse Bonwitt

Erin Whitehouse

Thank you!

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

